Splicing Factor HnRNP A2 Activates the Ras-MAPK-ERK Pathway by Controlling A-Raf Splicing in Hepatocellular Carcinoma Development

Overview

Journal RNA

Specialty Molecular Biology

Date 2014 Feb 28

PMID 24572810

Citations 62

Authors

Asaf Shilo

Vered Ben Hur

Polina Denichenko

Ilan Stein

Eli Pikarsky

Jens Rauch

Walter Kolch

Lars Zender

Rotem Karni

Affiliations

Soon will be listed here.

Abstract

In recent years, it has become clear that splicing factors play a direct role in cancer development. We showed previously that splicing factors SRSF1, SRSF6, and hnRNP A2/B1 are up-regulated in several cancers and can act as oncogenes when up-regulated. Here we examined the role of splicing factors hnRNP A1/A1b and hnRNP A2/B1 in hepatocellular carcinoma (HCC). We show that the splicing factors hnRNP A1 and hnRNP A2 are up-regulated in HCC tumors derived from inflammation-induced liver cancer mouse model. Overexpression of hnRNP A1 or hnRNP A2, but not the splicing isoform hnRNP B1, induced tumor formation of immortalized liver progenitor cells, while knockdown of these proteins inhibited anchorage-independent growth and tumor growth of human liver cancer cell lines. In addition, we found that cells overexpressing hnRNP A2 showed constitutive activation of the Ras-MAPK-ERK pathway. In contrast, knockdown of hnRNP A2 inhibited the Ras-MAPK-ERK pathway and prevented ERK1/2 activation by EGF. Moreover, we found that hnRNP A2 regulates the splicing of A-Raf, reducing the production of a short dominant-negative isoform of A-Raf and elevating the full-length A-Raf transcript. Taken together, our data suggest that hnRNP A2 up-regulation in HCC induces an alternative splicing switch that down-regulates a dominant-negative isoform of A-Raf, leading to activation of the Raf-MEK-ERK pathway and cellular transformation.

Citing Articles

Molecular targets and mechanisms of different aberrant alternative splicing in metastatic liver cancer.

Geng D, Chen Q, Chen W, Zhou L, Han X, Xie Q World J Clin Oncol. 2024; 15(4):531-539.

PMID: 38689626 PMC: 11056863. DOI: 10.5306/wjco.v15.i4.531.

Alternative splicing and related RNA binding proteins in human health and disease.

Tao Y, Zhang Q, Wang H, Yang X, Mu H Signal Transduct Target Ther. 2024; 9(1):26.

PMID: 38302461 PMC: 10835012. DOI: 10.1038/s41392-024-01734-2.

Ubiquitination and deubiquitination in the regulation of N-methyladenosine functional molecules.

Zhao Y, Huang J, Zhao K, Li M, Wang S J Mol Med (Berl). 2024; 102(3):337-351.

PMID: 38289385 DOI: 10.1007/s00109-024-02417-9.

Decoding the role of aberrant RNA alternative splicing in hepatocellular carcinoma: a comprehensive review.

Sheng M, Zhang Y, Wang Y, Liu W, Wang X, Ke T J Cancer Res Clin Oncol. 2023; 149(19):17691-17708.

PMID: 37898981 DOI: 10.1007/s00432-023-05474-8.

Decoding mA mRNA methylation by reader proteins in liver diseases.

Sun L, Chen X, Zhu S, Wang J, Diao S, Liu J Genes Dis. 2023; 11(2):711-726.

PMID: 37692496 PMC: 10491919. DOI: 10.1016/j.gendis.2023.02.054.

References

Pratilas C, Solit D . Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res. 2010; 16(13):3329-34. PMC: 2912210. DOI: 10.1158/1078-0432.CCR-09-3064. View

Wang L, Liu H, Li Y, Yuan P . Proteomic analysis of pancreatic intraepithelial neoplasia and pancreatic carcinoma in rat models. World J Gastroenterol. 2011; 17(11):1434-41. PMC: 3070016. DOI: 10.3748/wjg.v17.i11.1434. View

Fielding P, Turnbull L, Prime W, Walshaw M, Field J . Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin Cancer Res. 2000; 5(12):4048-52. View

LeFave C, Squatrito M, Vorlova S, Rocco G, Brennan C, Holland E . Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J. 2011; 30(19):4084-97. PMC: 3209773. DOI: 10.1038/emboj.2011.259. View

Tiniakos D, Spandidos D, Kakkanas A, Pintzas A, Pollice L, Tiniakos G . Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res. 1989; 9(3):715-21. View

Waki K, Anno K, Ono T, Ide T, Chayama K, Tahara H . Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere-targeting anticancer drug development. Cancer Sci. 2010; 101(7):1678-85. PMC: 11159078. DOI: 10.1111/j.1349-7006.2010.01576.x. View

Mark G, Seeley T, Shows T, Mountz J . Pks, a raf-related sequence in humans. Proc Natl Acad Sci U S A. 1986; 83(17):6312-6. PMC: 386493. DOI: 10.1073/pnas.83.17.6312. View

Hanamura A, Caceres J, Mayeda A, Franza Jr B, Krainer A . Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA. 1998; 4(4):430-44. PMC: 1369629. View

Rauch J, ONeill E, Mack B, Matthias C, Munz M, Kolch W . Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 2010; 70(4):1679-88. PMC: 2880479. DOI: 10.1158/0008-5472.CAN-09-2740. View

10.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

11.

Challen C, Guo K, Collier J, Cavanagh D, Bassendine M . Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol. 1992; 14(2-3):342-6. DOI: 10.1016/0168-8278(92)90181-n. View

12.

Chan K, Guan X, Ng I . High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol. 2005; 35(11):1324-31. DOI: 10.1016/j.humpath.2004.06.012. View

13.

Rauch J, Ahlemann M, Schaffrik M, Mack B, Ertongur S, Andratschke M . Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem Biophys Res Commun. 2004; 323(1):156-62. DOI: 10.1016/j.bbrc.2004.08.071. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Clower C, Chatterjee D, Wang Z, Cantley L, Vander Heiden M, Krainer A . The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010; 107(5):1894-9. PMC: 2838216. DOI: 10.1073/pnas.0914845107. View

16.

Karni R, de Stanchina E, Lowe S, Sinha R, Mu D, Krainer A . The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14(3):185-93. PMC: 4595851. DOI: 10.1038/nsmb1209. View

17.

Zhou J, Nong L, Wloch M, Cantor A, Mulshine J, Tockman M . Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001; 34(3):341-50. DOI: 10.1016/s0169-5002(01)00254-9. View

18.

Calvisi D, Ladu S, Gorden A, Farina M, Conner E, Lee J . Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006; 130(4):1117-28. DOI: 10.1053/j.gastro.2006.01.006. View

19.

Anczukow O, Rosenberg A, Akerman M, Das S, Zhan L, Karni R . The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012; 19(2):220-8. PMC: 3272117. DOI: 10.1038/nsmb.2207. View

20.

Niault T, Baccarini M . Targets of Raf in tumorigenesis. Carcinogenesis. 2010; 31(7):1165-74. DOI: 10.1093/carcin/bgp337. View